Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

被引：0
|
作者：
Ledermann, J. A. [1 ,2 ]
Shapira-Frommer, R. [3 ]
Santin, A. [4 ]
Lisyanskaya, A. S. [5 ]
Pignata, S. [6 ]
Vergote, I. [7 ]
Raspagliesi, F. [8 ]
Sonke, G. S. [9 ]
Birrer, M. J. [10 ]
Provencher, D. M. [11 ]
Sehouli, J. [12 ]
Colombo, N. [13 ,14 ]
Gonzalez-Martin, A. [15 ]
Oaknin, A. [16 ]
Ottevanger, P. B. [17 ]
Rudaitis, V. [18 ]
Cristescu, R. [19 ]
Kobie, J. [19 ]
Ruman, J. [19 ]
Matulonis, U. A. [20 ]
机构：
[1] UCL, CRUK, London, England
[2] UCL, UCL Canc Inst, UCL Canc Trials Ctr, London, England
[3] Sheba Med Ctr, Med Oncol, Ramat Gan, Israel
[4] Yale Sch Med, Gynecol Oncol, New Haven, CT USA
[5] St Petersburg City Oncol Hosp, Oncogynaecol, St Petersburg, Russia
[6] Ist Nazl Tumori Napoli, Dipartimento Uroginecol, Naples, Italy
[7] Univ Hosp Leuven, Obstet & Gynecol & Gynecol Oncol, Leuven, Belgium
[8] Fdn IRCCS Ist Nazl Tumori Milan, Surg, Milan, Italy
[9] Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands
[10] Univ Alabama Birmingham, Hematol & Oncol, Birmingham, AL USA
[11] Ctr Hosp Univ Montreal, Med Oncol, Montreal, PQ, Canada
[12] Charite Med Univ Berlin, Med Oncol, Berlin, Germany
[13] Univ Milano Bicocca, Gynecol Oncol, Milan, Italy
[14] IRCCS Milan, European Inst Oncol, Milan, Italy
[15] Clin Univ Navarra, Med Oncol, Madrid, Spain
[16] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Oncol, Barcelona, Spain
[17] Radboud Univ Nijmegen, Med Ctr, Med Oncol, Nijmegen, Netherlands
[18] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania
[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[20] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA36
引用
收藏
页码：728 / 728
页数：1
相关论文
共 50 条
  • [1] Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
    Matulonis, U. A.
    Shapira-Frommer, R.
    Santin, A. D.
    Lisyanskaya, A. S.
    Pignata, S.
    Vergote, I
    Raspagliesi, F.
    Sonke, G. S.
    Birrer, M.
    Provencher, D. M.
    Sehouli, J.
    Colombo, N.
    Gonzalez-Martin, A.
    Oaknin, A.
    Ottevanger, P. B.
    Rudaitis, V
    Katchar, K.
    Wu, H.
    Keefe, S.
    Ruman, J.
    Ledermann, J. A.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1080 - 1087
  • [2] KEYNOTE-100: Phase 2 trial of pembrolizumab in patients with advanced recurrent ovarian cancer
    Matulonis, U. A.
    Chen, M.
    Puhlmann, M.
    Shentu, Y.
    Ledermann, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100
    Ledermann, J. A.
    Shapira-Frommer, R.
    Santin, A. D.
    Lisyanskaya, A.
    Pignata, S.
    Vergote, I. B.
    Raspagliesi, F.
    Sonke, G. S.
    Birrer, M.
    Provencher, D.
    Sehouli, J.
    Colombo, N.
    Gonzalez Martin, A.
    Oaknin, A.
    Saadatpour, A.
    Kobie, J.
    Jelinic, P.
    Stein, K.
    Matulonis, U. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S631 - S632
  • [4] Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
    Matulonis, Ursula A.
    Shapira, Roni
    Santin, Alessandro
    Lisyanskaya, Alla Sergeevna
    Pignata, Sandro
    Vergote, Ignace
    Raspagliesi, Francesco
    Sonke, Gabe S.
    Birrer, Michael
    Sehouli, Jalid
    Colombo, Nicoletta
    Gonzalez-Martin, Antonio
    Oaknin, Ana
    Ottevanger, P. B.
    Rudaitis, Vilius
    Wu, Haiyan
    Keefe, Stephen Michael
    Stein, Karen
    Ledermann, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study
    Matulonis, Ursula A.
    Shapira-Frommer, Ronnie
    Santin, Alessandro
    Lisyanskaya, Alla Sergeevua
    Pignata, Sandro
    Vergote, Ignace
    Raspagliesi, Francesco
    Sonke, Gabe S.
    Birrer, Michael
    Provencher, Diane M.
    Sehouli, Jalid
    Colombo, Nicoletta
    Gonzalez-Martin, Antonio
    Oaknin, Ana
    Ottevanger, P. B.
    Rudaitis, Vilius
    Katchar, Kia
    Wang, Zhen
    Ruman, Jane
    Ledermann, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer
    Kim, G.
    Ahn, S.
    Hwang, J-H.
    Lee, J-C.
    Kim, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] ASSOCIATION OF T-CELL-INFLAMED GENE EXPRESSION PROFILE AND PD-L1 STATUS WITH EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH ESOPHAGEAL CANCER FROM KEYNOTE-180
    Shah, Manish
    Kojima, Takashi
    Hochhauser, Daniel
    Enzinger, Peter
    Raimbourg, Judith
    Hollebecque, Antoine
    Lordick, Florian
    Kim, Sung-Bae
    Tajika, Masahiro
    Kim, Heung Tae
    Lockhart, A. Craig
    Arkenau, Hendrick-Tobias
    El-Hajbi, Farid
    Pfeiffer, Per
    Bhagia, Pooja
    Cao, Z. Alexander
    Lunceford, Jared
    Suryawanshi, Shailaja
    Ayers, Mark
    Marton, Matt
    Kato, Ken
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A159 - A160
  • [8] PD-L1 EXPRESSION AND EFFICACY IN PATIENTS TREATED WITH PEMBROLIZUMAB VS IPILIMUMAB FOR ADVANCED MELANOMA IN KEYNOTE-006
    Carlino, M.
    Emancipator, K.
    Ibrahim, N.
    Zhou, H.
    Schadendorf, D.
    Ribas, A.
    Gonzalez, R.
    Hoeller, C.
    Bar-Sela, G.
    Barrow, C.
    Chao, D.
    Wolter, P.
    Berking, C.
    Straume, O.
    Berrocal, A.
    Holgado, E.
    Gangadhar, T. C.
    Weiss, G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 44 - 44
  • [9] PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
    Khattak, Muhammad A.
    Reid, Anna
    Freeman, James
    Pereira, Michelle
    McEvoy, Ashleigh
    Lo, Johnny
    Frank, Markus H.
    Meniawy, Tarek
    Didan, Ali
    Spencer, Isaac
    Amanuel, Benhur
    Millward, Michael
    Ziman, Melanie
    Gray, Elin
    ONCOLOGIST, 2020, 25 (03): : E520 - E527
  • [10] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
    Miyakoshi, Jun
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Ohe, Yuichiro
    CANCER RESEARCH, 2024, 84 (06)
12345